Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
A phase 3 trial of 177Lu-edotreotide, Temozolomide, Capecitabine, Everolimus, Leucovorin (folinic acid) and Oxaliplatin in neuroendocrine tumours, run by ITM Solucin GmbH, active and no longer recruiting.
Overview
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE is a phase 3 interventional study registered as NCT04919226 by ITM Solucin GmbH, with 259 participants enrolled, started 2021-12-21 and due to reach its primary completion in 2027-06. Interventions recorded: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Everolimus and FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin).
Similar pages
not linked directly; found by shared links- TrialStudy to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Shares Grade 3 well-differentiated neuroendocrine tumour, Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Neuroendocrine tumours and the tag pipeline.
- TrialA Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
Shares Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Neuroendocrine tumours, Lutetium-177 and the tag pipeline.
- TrialA Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
Shares Capecitabine, Lutetium-177 and the tag pipeline.
- TrialAn Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Shares Pancreatic neuroendocrine tumours, Lutetium-177 and the tag pipeline.
- TrialA Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
Shares Neuroendocrine tumours, Lutetium-177 and the tag pipeline.
- TrialA Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Shares Neuroendocrine tumours and the tag pipeline.
- TrialPhase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Shares Lutetium-177 and the tag pipeline.
- TrialA Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
Shares Lutetium-177 and the tag pipeline.